Sonneries Logos - Presse Algerie -    DOcuments PDF PPT Word en ligne
 
     
Forum Medical de sante Pro

Pdf Documentation



Forum.Org Forum Algérien de Médecine
forum de medecine,discussion diagnostique,annuaire sante algerieinfo residanat,concours etudiants,qcm,examen chirurgie annonces medicales

* Démission de l'hopital : 25/03/17 - Bonjour , j'aimerais savoir quel sont les etapes a suivre pour demissioner de la fonction publique pour un medecin qui travail dans un hopital faut il deposer sa demission au chef de service puis...
* Pipi au lit enfant plus de 5 ans solution : 23/03/17 - video youtube : Pipi au lit enfant plus de 5 ans solution (https://youtu.be/mIkpDhty96s)
* Rétinopathie diabétique: définition physiopathologie Classification : 12/03/17 - *Rétinopathie diabétique: définition physiopathologie Classification : * vidéo : https://youtu.be/m1P8bFcJC9g
* Interprétation de L'Électrocardiogramme: ischémie et infarctus du myocarde : 11/03/17 - Interprétation de L'Électrocardiogramme: ischémie et infarctus du myocarde: https://www.youtube.com/watch?v=LGGuBCGo2ak&t=7s&list=PLhoyRnuxANN_vxVp57cojsZcrzqpZWtsw&index=31 le lien pour...
* Syndrome myogène (Myopathique) vidéo : 04/03/17 - Vidéo durée 27:11 sur Le Syndrome myogène (Myopathique): https://www.youtube.com/watch?v=HtG8ZaZl0yc
* Syndrome de Raynaud phénomène et maladie diagnostic Traitement : 25/02/17 - Syndrome de Raynaud phénomène et maladie diagnostic Traitement https://youtu.be/1ZPNFc8AGsg

Complémentaire Santé news

: Forum.Org Complementaire Formation Sante Congres medecine biologie
Actualité scientifique mondiale

* Time to clinically relevant fracture risk scores in postmenopausal women : 09/03/17 - Publication date: Available online 9 March 2017
Source:The American Journal of Medicine
Author(s): Margaret L. Gourlay, Robert A. Overman, Jason P. Fine, Carolyn J. Crandall, John Robbins, John T. Schousboe, Kristine E. Ensrud, Erin S. LeBlanc, Margery L. Gass, Karen C. Johnson, Catherine R. Womack, Andrea Z. LaCroix
BackgroundClinical practice guidelines recommend use of fracture risk scores for screening and pharmacologic treatment decisions. The timing of occurrence of treatment-level (according to 2014 National Osteoporosis Foundation guidelines) or screening-level (according to 2011 US Preventive Services Task Force guidelines) fracture risk scores has not been estimated in postmenopausal women.MethodsWe conducted a retrospective competing risk analysis of new occurrence of treatment-level and screening-level fracture risk scores in postmenopausal women aged 50 and older, before receipt of pharmacologic treatment and before first hip or clinical vertebral fracture.ResultsIn 54,280 postmenopausal women aged 50 to 64 without a bone mineral density test, the time for 10% to develop a treatment-level FRAX® could not be estimated accurately because of rare incidence of treatment-level scores. In 6096 women who had FRAX scores calculated with bone mineral density, the estimated unadjusted time to treatment-level FRAX ranged from 7.6 years (95% CI, 6.6, 8.7) for those aged 65 to 69 to 5.1 years (95% CI, 3.5, 7.5) for those aged 75 to 79 at baseline. Of 17,967 women aged 50 to 64 with a screening-level FRAX at baseline, 100 (0.6%) experienced a hip or clinical vertebral fracture by age 65.ConclusionsPostmenopausal women with sub-threshold fracture risk scores at baseline were unlikely to develop a treatment-level FRAX score between ages 50 and 64. After age 65, the increased incidence of treatment-level fracture risk scores, osteoporosis and major osteoporotic fracture supports more frequent consideration of FRAX and bone mineral density testing.


* Traitements anti-résorptifs pour le traitement et la prévention des métastases osseuses : 09/03/17 - Publication date: Available online 9 March 2017
Source:Revue du Rhumatisme Monographies
Author(s): Françoise Debiais
Les traitements inhibiteurs de la résorption osseuse jouent un rôle important dans la prise en charge des métastases osseuses. Bisphosphonates et dénosumab ont montré une efficacité pour retarder la survenue des complications osseuses chez les patients ayant des métastases osseuses. Dans d’importantes études randomisées, le dénosumab a montré une supériorité par rapport à l’acide zolédronique pour retarder la survenue de la première complication osseuse en cas de cancer du sein ou de prostate avec métastases osseuses, et une non-infériorité a été retrouvée dans l’étude concernant les autres tumeurs. Des questions concernant la durée du traitement, le meilleur rythme d’administration des traitements persistent. L’intérêt de ces traitements en adjuvant avant la survenue des métastases osseuses est en cours d’évaluation ; des données récentes avec l’utilisation des bisphosphonates en traitement adjuvant chez les patientes ayant un cancer du sein, pourraient changer la pratique clinique, en particulier chez les femmes ménopausées ayant un cancer du sein à haut risque de rechute.Bone-targeted treatments play an important role in the management of malignant tumor osteolysis. Bisphosphonates and denosumab have demonstrated their efficacity for delaying the time to skeletal-related event (SRE) in patients with bone metastases. In large randomized trials, denosumab was more effective than zoledronic acid in preventing skeletal morbidity in patients with breast or prostate cancer with bone metastases, and non-inferiority was shown in the trial with other solid tumors. Questions concerning the duration of the treatment, the optimal dosing interval remain. The interest of these treatments as adjuvant therapy before the occurrence of bone metastases is currently being evaluated; recent data with adjuvant bisphosphonate treatment in breast cancer could change clinical practice, especially in postmenopausal women with breast cancer at high risk of recurrence.


* Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up) : 09/03/17 - Publication date: Available online 9 March 2017
Source:Bone
Author(s): Benjamin Z. Leder, Joy N. Tsai, Linda Jiang, Hang Lee
When teriparatide and denosumab are discontinued, bone mineral density (BMD) abruptly decreases. To compare rates of bone loss in postmenopausal women who discontinue denosumab or teriparatide and receive no additional prescription osteoporosis medications to women who discontinue these drugs followed by prompt antiresorptive therapy, we asked women concluding the Denosumab and Teriparatide Administration (DATA) study and its extension, DATA-Switch, to return for BMD measurements at 1–2years after study completion. In these studies, women received 2-years of either teriparatide, denosumab or both medications followed by 2-years of the alternate therapy (women who received combination therapy initially received an additional 2-years of denosumab alone).Fifty of 69 women who completed DATA-Switch returned after a mean of 15.4±3.5months. Of the 28 women who received antiresorptive therapy (10 denosumab, 10 oral bisphosphonates, 8 intravenous zoledronic acid), the mean interval between ending DATA-Switch and beginning antiresorptive therapy was 3.8±3.1months. In the 22 women not receiving follow-up therapy, femoral neck, total hip, and spine BMD decreased by −4.2±4.3%, −4.5±3.6%, and −10.0±5.4%, respectively, while BMD was maintained in those who did receive follow-up antiresorptive drugs (femoral neck, total hip, and spine BMD changes of −0.6±2.7%, −0.8±3.1%, and −1.2±4.7%, respectively, P<0.001 for all between-group comparisons). Among untreated women, femoral neck BMD decreased more in those discontinuing denosumab (−5.8±4.0%) than in those discontinuing teriparatide (−0.8±2.6%, P=0.008). Total hip BMD, but not spine BMD, showed a similar pattern. Among treated women, denosumab increased femoral neck and total hip BMD more than bisphosphonates while BMD changes at the spine did not differ significantly.In summary, the large teriparatide and denosumab-induced gains in BMD achieved with 4years of intensive therapy in the DATA and DATA-Switch studies were maintained in patients who received prompt antiresorptive therapy but not in those left untreated. These results demonstrate the negative consequences of delaying consolidation therapy in women treated with these drugs and underscore the importance of timely medication transitions in such patients.


* The effects of parathyroid hormone peptides on the peripheral skeleton of postmenopausal women. A systematic review : 09/03/17 - Publication date: Available online 9 March 2017
Source:Bone
Author(s): Louis M. Metcalf, Terry J. Aspray, Eugene V. McCloskey
Given current developments in anabolic therapy for bone, we wished to document the effects of the only currently available anabolic therapy, parathyroid hormone (PTH) peptides, on the peripheral skeleton of postmenopausal women.We undertook a systematic review of English articles using MEDLINE, Scopus and the Cochrane Controlled Trials Register (final update 28th March 2016). Additional studies were identified through searches of bibliographies. Studies included those comparing PTH peptides with placebo, with anti-osteoporotic treatments and in combination therapies. Participants had to be postmenopausal women and outcomes included areal or volumetric bone mineral density (BMD) and measurements of bone microarchitecture at peripheral sites, such as the forearm and tibia. Data were extracted independently and reviewed by EMcC and LMM. Data on study design were also collected for methodological risk of bias assessment.The heterogeneity between studies, regarding the drug dose and duration, and the site measured, prevented grouped meta-analysis. There were no significant differences in areal BMD between PTH peptides and placebo at peripheral skeletal sites at 12months. A decrease in aBMD occurred with PTH(1–34) (larger dose) and PTH(1–84) treatment at 18months follow-up in comparison to the placebo arms. Anti-resorptives seemed to attenuate losses of aBMD at peripheral sites when compared to PTH peptides monotherapy, likely mediated by lower cortical porosity. Finally, PTH peptides combined with bisphosphonates or denosumab attenuated peripheral BMD losses in comparison to PTH peptide monotherapy, with evidence of increased BMD at ultradistal peripheral sites when PTH(1–34) was combined with denosumab or hormone replacement therapy.This summary should act as a reference point for the comparison of new anabolic therapies, specifically in comparison to PTH(1–34).


* les troisièmes journées tunisiennes d’organisation hospitalière (JTOH?3) : 09/03/17 - Congres médical/Evénement qui aura lieu le : 2017-04-20 : Spécialité: Informatique médical

Cher(es) Amis(es);

L’organisation hospitalière prend de plus en plus d’ampleur, tant les intervenants sont nombreux, les technologies utilisées poussées et les situations complexes. Cet intérêt s’est traduit par l’organisation de 2 journées scientifiques par le Groupe de Recherche et d’Expertise en Hospitalier (GREHOSP) : les journées tunisiennes d’organisation hospitalière (JTOH)’1en 2015 et JTOH’2 en 2016.
Cette année, le GREHOSP, en collaboration avec l’U...

* 14e Journée de Radiologie Hépato-Biliaire : 09/03/17 - Congres médical/Evénement qui aura lieu le : 2017-06-10 : Spécialité: Radiologie / Imagerie

Il est essentiel de renseigner cette description qui est votre espace personnel de promotion pour cet événement ainsi que pour son référencement.14E JOURNEE DE RADIOLOGIE HEPATO-BILIAIRE
DU GROUPE HOSPITALIER BICETRE - PAUL BROUSSE
SAMEDI 10 JUIN 2017
Organisée par Marie-France Bellin, Francis Kunstlinger et Maïté Lewin
NEW CAP EVENT CENTER (CAP 15)
13 QUAI DE GRENELLE - 75015 PARIS

Cette journée sera consacrée à l’imagerie hépatobiliaire et à l&rsquo...

* The Effect of A Geriatric Assessment on Treatment Decisions for Patients with Lung Cancer : 09/03/17 -

Abstract

Background

Decision-making for older patients with lung cancer can be complex and challenging. A geriatric assessment (GA) may be helpful and is increasingly being used since 2005 when SIOG advised to incorporate this in standard work-up for the elderly with cancer. Our aim was to evaluate the value of a geriatric assessment in decision-making for patients with lung cancer.

Methods

Between January 2014 and April 2016, data on patients with lung cancer from two teaching hospitals in the Netherlands were entered in a prospective database. Outcome of geriatric assessment, non-oncologic interventions, and suggested adaptations of oncologic treatment proposals were evaluated.

Results

83 patients (median age 79 years) were analyzed with a geriatric assessment, of which 59% were treated with a curative intent. Half of the patients were classified as ECOG PS 0 or 1. The majority of the patients (78%) suffered from geriatric impairments and 43% (n = 35) of the patients suffered from three or more geriatric impairments (out of eight analyzed domains). Nutritional status was most frequently impaired (52%). Previously undiagnosed impairments were identified in 58% of the patients, and non-oncologic interventions were advised for 43%. For 33% of patients, adaptations of the oncologic treatment were proposed. Patients with higher number of geriatric impairments more often were advised a reduced or less intensive treatment (p < 0.001).

Conclusion

A geriatric assessment uncovers previously unknown health impairments and provides important guidance for tailored treatment decisions in patients with lung cancer. More research on GA-stratified treatment decisions is needed.


* Oxidative potential (OP) and mineralogy of iron ore particulate matter at the Gol-E-Gohar Mining and Industrial Facility (Iran) : 09/03/17 -

Abstract

Concentrations of total suspended particulate matter, particulate matter with aerodynamic diameter <2.5 μm (PM2.5), particulate matter <10 μm (PM10), and fallout dust were measured at the Iranian Gol-E-Gohar Mining and Industrial Facility. Samples were characterized in terms of mineralogy, morphology, and oxidative potential. Results show that indoor samples exceeded the 24-h PM2.5 and PM10 mass concentration limits (35 and 150 µg m−3, respectively) set by the US National Ambient Air Quality Standards. Calcite, magnetite, tremolite, pyrite, talc, and clay minerals such as kaolinite, vermiculite, and illite are the major phases of the iron ore PM. Accessory minerals are quartz, dolomite, hematite, actinolite, biotite, albite, nimite, laumontite, diopside, and muscovite. The scanning electron microscope structure of fibrous-elongated minerals revealed individual fibers in the range of 1.5 nm to 71.65 µm in length and 0.2 nm to 3.7 µm in diameter. The presence of minerals related to respiratory diseases, such as talc, crystalline silica, and needle-shaped minerals like amphibole asbestos (tremolite and actinolite), strongly suggests the need for detailed health-based studies in the region. The particulate samples show low to medium oxidative potential per unit of mass, in relation to an urban road side control, being more reactive with ascorbate than with glutathione or urate. However, the PM oxidative potential per volume of air is exceptionally high, confirming that the workers are exposed to a considerable oxidative environment. PM released by iron ore mining and processing activities should be considered a potential health risk to the mine workers and nearby employees, and strategies to combat the issue are suggested.


* Journées de l?ADEESSE : 09/03/17 - Congres médical/Evénement qui aura lieu le : 2017-10-13 : Spécialité: Dermatologie

L'Association de Dermatologie Esthétique du Sud Est organise ses journées annuelles au Parc Chanot à Marseille.
Cette année, l'association fête ses 10 ans.
...

* glaucoma; +32 new citations : 09/03/17 - 32 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: glaucoma These pubmed results were generated on 2017/03/09PubMed comprises more than millions of citations for biomedi...

Journaux : elmoudjahid  elwatan   lematindz  Tsa-algerie 

Nouveautés Livre Revue Scolaire Préparations au Concours

 

  1. Calcule Biologique
  2. Annuaire de Sante
  3. S'inscrire au MedSante
  4. Dictionnaire medicale
  5. Forumed des médecins
  6. Université Sciences Medicales
  7. Health.cat News
  8. Cours de Medecine
Occupational Hygiene
Bioinformatics journal
Oncology-journal
Rheumatology journal
Human Reproduction

Cardiology
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics/Aging
Hematology/Oncology
Immunology/Allergy
Infectious Disease
Nephrology
Neurology/Neurosurgery
Obstetrics/Gynecology
Pediatrics
Psychiatry
Public Health, Policy, and Training
Pulmonary
Rheumatology
Surgery

sitemap  Copyright © 2004/2010 Sante-dz.org sitemap.xml